hotspot -WSS

hotspot

author：hotspot 2025-10-01 04:10:55 - browse：93

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

To hear Sarepta CEO Doug Ingram tell it, the results Monday afternoon from a large trial of its gene therapy for Duchenne muscular dystrophy marked a clear medical breakthrough. “A massive win,” he told investors, that could lead to its approval for all patients with the fatal muscle-wasting disease regardless of age.

And yet the rest of the Duchenne community was more cautious in its enthusiasm. The study — the most rigorous test to date of a technology 30 years in the making — had technically failed, as so many had before it.

“It’s extremely frustrating,” said John Brandsema, a pediatric neurologist at Children’s Hospital of Philadelphia who worked on the study. “When you spend decades trying to bring therapies into the clinic for something so severe and just keep missing over and over again.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Cytokinetics CEO stresses company can launch heart drug on its own

WSS

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

It's time to retire 'poor historian' from clinicians' vocabularies

Bird flu in milk supply is likely coming from asymptomatic cows

Orangutan used medicinal plant to treat wound, first time ever seen

When prostate cancer spreads, where it goes matters

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

explore

hotspot

focus

Psychedelics group wrestles with new pharma identity

Element Biosciences CEO lays out genome sequencing strategy

BioMarin wins approval for gene therapy to treat hemophilia A

Addiction experts warn against a second 'war on drugs'

At least 13 dead in Texas as scorching temps continue

It's time to retire 'poor historian' from clinicians' vocabularies

United colonoscopy coverage change 'may cost lives,' doctors say

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Activists slam private health insurers over coverage restrictions

Criminal prosecution for violating HIPAA: an emerging threat

entertainment

After traumatic brain injury, life support decisions can use more time

Wellcome Trust’s new CEO hopes Big Tech gets more involved in public health

Exact Sciences stock tumbles despite strong cancer detection sales

Addiction experts warn against a second 'war on drugs'

Cue Health's Covid

Bird flu outbreak in cows is latest avian flu curveball

entertainment

focus

focus

focus